Airsonett expands into Italy by signing distributor contract with INNOVACAREMD

Airsonett announced today that the company is expanding into the Italian market through a distributor partnership with INNOVACAREMD. The company will distribute Airsonett’s unique medical device for TLA treatment (Temperature-controlled Laminar Airflow), the patented and effective treatment of allergic diseases such as allergic asthma and atopic eczema.

The partnership is the next step forward in Airsonett's strategy to expand into selected European markets. Italy has a population of approximately 60 million, where 12 million (20%) suffer from allergic diseases. It is estimated that there are 2,7 million asthmatics in Italy, of whom approximately 300 000 have severe asthma. Atopic eczema affects between 15-30% of children and 2-10% of adults in industrial countries. In Italy, this could translate to between 1-2 million children suffering from atopic eczema.

“We are excited that INNOVACAREMD has agreed to be our distributor in Italy. They have set ambitious goals and have extensive experience of the public healthcare system in Italy. We believe Mr Scorsato and the organization is positioned to deliver results. We look forward to introducing TLA treatment to the Italian health care professionals and their patients," said Anders Due-Boje, CEO of Airsonett.

Marco Scorsato, CEO of INNOVACAREMD, said: "Airsonett and the TLA-treatment have been on our radar for some time. We foresee an excellent potential for this effective treatment, so we are very eager to educate our health care community about its advantages. Our organization's collected experience from companies such as Pharmacia, Pfizer, Phadia and Atos gives us the market insight and network to make Airsonett a success also in Italy".

For more information:
Anders Due-Boje, CEO, Airsonett AB
Phone: +46 70 526 03 00
E-mail: anders.due-boje@airsonett.eu

Marco Scorsato, CEO, INNOVACAREMD
Phone: +39 3357563418
E-mail: marco.scorsato@innovacaremd.com

About Airsonett
Airsonett® is a Swedish medical device company that leads the way in the development of non-pharmacologic treatment of allergic severe asthma and eczema. Airsonett® Air4 is a non-invasive device for treatment in the home, based on the patented Temperature-controlled Laminar Airflow technology (TLA). Treatment with the Airsonett® Air4 significantly reduces allergens and other airborne irritants from the patient’s breathing zone during rest and sleep. Airsonett® Air4 is a CE marked class 1 medical device intended to be used for the alleviation of symptoms of allergy-induced diseases such as allergic asthma and eczema. It adheres to relevant EU directives regarding design, function, safety and health requirements and has undergone rigorous clinical research as well as health-economic studies. Airsonett® Air4 holds a 510(k) cleared class II approval from FDA. The company’s main shareholders are SEB Venture Capital, Industrifonden and Magnus Lundberg. For more information visit www.airsonett.eu

About INNOVACAREMD
INNOVACAREMD is an Italian company specialized in the marketing of high-tech products and services in the field of advanced health research. The main mission is to improve people's health through innovative medical technologies. The company is always looking for new products to respond to the patient's clinical needs.

INNOVACAREMD is the exclusive distributor for the Italian market of Airsonett® Air4 the medical device for effective home treatment of allergic asthma and eczema. For more information visit www.innovacaremd.com

About severe, uncontrolled asthma
Patients with severe, uncontrolled asthma treated according to Global Initiative for Asthma (GINA) step 4/5 account for approximately 3% of all patients with persistent asthma, according to recent population-based studies using administrative and prescribed databases, but account for a much larger share of asthma-related healthcare resource use and costs. Treatment alternatives for such patients include high-dose inhaled corticosteroids (ICS) and long-acting β2-antagonists (LABAs) and/or systematic corticosteroids. During the last decade, several new drugs for the treatment of severe asthma have been developed, and some of these drugs, such as anti-immunoglobulin E and anti-interleukin 5 have been included in Step 5 in the latest GINA recommendations. The costs for treatment with these biologics are however very high. Temperature-controlled laminar airflow (TLA) is an effective treatment for patients with severe, uncontrolled asthma. The use of TLA has shown cost-effectiveness according to National Institute for Health and Care Excellence (NICE) standards and the Swedish Dental and Pharmaceutical Benefits Agency, TLV, a central government agency whose remit is to determine whether a pharmaceutical product, medical device or dental care procedure shall be subsidized by the state.